Ross Stores, Inc. vs Revvity Inc — how do they compare? Ross Stores, Inc. trades at $248.53 (market cap $80.78B), while Revvity Inc trades at $115.95 (market cap $12.91B). The key difference: Ross Stores, Inc. is far larger — about 6.3× Revvity Inc's market cap, and Ross Stores, Inc. pays the higher dividend (0.71%). Which is the better fit depends on your goals.
| ROST | RVTY | |
|---|---|---|
Market Cap | $80.78B | $12.91B |
Sector | Consumer Cyclical | Technology |
52-Week High | $255.23 | $117.75 |
52-Week Low | $144.67 | $82.26 |
Enterprise Value | $81.37B | $15.23B |
Dividend Yield | 0.71% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
ROST trades at $250.45, down 1.72% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $259.00. The company has consistently beaten earnings estimates, with Q1 2026 EPS of $2.02 exceeding the $1.73 forecast. Strong fundamentals include a net income margin of 9.74% and ROE of 38.98%, supported by revenue growth to $21.13 billion in 2025 and recent expansion with 47 new stores opened in mid-2026.
The outlook remains positive given earnings momentum and store growth, but elevated valuation ratios like a P/E of 35.17 pose a risk if growth slows. Analyst sentiment is bullish with 64% buy ratings, though technical indicators show mixed signals with RSI near overbought levels. Investors should weigh robust profitability against high multiples in a competitive retail sector.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →